

1 **Title:**

2 Molecular epidemiology of invasive Group A Streptococcal infections before and after the  
3 COVID-19 pandemic in Switzerland

4 **Authors:**

5 Angeliki M. Andrianaki<sup>1</sup>, Jessica Franz<sup>1</sup>, Federica Andreoni<sup>1</sup>, Judith Bergada-Pijuan<sup>1</sup>,  
6 Thomas C. Scheier<sup>1</sup>, Tanja Duwe<sup>1</sup>, Marc Pfister<sup>1</sup>, Helena Seth-Smith<sup>2</sup>, Tim Roloff<sup>2</sup>, Natalia  
7 Kolesnik-Goldmann<sup>2</sup>, Sara H. Burkhard<sup>3</sup>, Alexia Cusini<sup>4</sup>, Urs Karrer<sup>5</sup>, Christian Rüegg<sup>6</sup>,  
8 Adrian Schibli<sup>7</sup>, Jacques Schrenzel<sup>8</sup>, Stefano Musumeci<sup>9</sup>, Roger D. Kouyos<sup>1</sup>, Adrian Egli<sup>2</sup>,  
9 Silvio D. Brugger<sup>1</sup>, Annelies S. Zinkernagel<sup>1\*</sup>

10 **Affiliations:**

- 11 1. Department of Infectious Diseases and Hospital Epidemiology, University Hospital  
12 Zurich, University of Zurich, Zurich, Switzerland
- 13 2. Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
- 14 3. Division of Infectious Diseases, Department of Medicine, Hospital of Uster, Uster,  
15 Switzerland
- 16 4. Division of Infectious Diseases, Cantonal Hospital of Grisons, Chur, Switzerland
- 17 5. Division of Infectious Diseases, Department of Medicine, Cantonal Hospital of  
18 Winterthur, Winterthur, Switzerland
- 19 6. Division of Infectious Diseases, Department of Medicine, Hospital of Wetzikon,  
20 Wetzikon, Switzerland
- 21 7. Division of Infectious Diseases and Hospital Epidemiology, Zurich City Hospital,  
22 Zurich, Switzerland
- 23 8. Division of Laboratory Medicine, Geneva University Hospitals, Switzerland; Division  
24 of Infectious Diseases, Geneva University Hospitals, Switzerland.

25 9. Department of General Internal Medicine, Department of Medicine, Geneva  
26 University Hospital, 1205 Geneva, Switzerland.

27

28 Corresponding author:

29 Prof. Dr. Dr. med. Annelies Zinkernagel

30 Department of Infectious Diseases and Hospital Epidemiology

31 University Hospital of Zurich,

32 Raemistrasse 100, 8091 Zurich, Switzerland

33 Tel: + 44 255 33 22

34 E-Mail: [annelies.zinkernagel@usz.ch](mailto:annelies.zinkernagel@usz.ch)

35

36 **Keywords:** Group A Streptococcus, GAS, COVID-19, emm-type, FT-IR spectroscopy, whole  
37 genome sequencing, WGS

38 **Abstract**

39 Group A *Streptococcus* (GAS, aka *Streptococcus pyogenes*) poses a significant public health  
40 concern, causing a diverse spectrum of infections with high mortality rates. Following the  
41 COVID-19 pandemic, a resurgence of invasive GAS (iGAS) infections has been documented,  
42 necessitating efficient outbreak detection methods. Whole genome sequencing (WGS) serves  
43 as the gold standard for GAS molecular typing, albeit constrained by time and costs. This  
44 study aimed to characterize the post-pandemic increased prevalence of iGAS on the molecular  
45 epidemiological level in order to assess whether new, more virulent variants have emerged, as  
46 well as to assess the performance of the rapid and cost-effective Fourier-transform infrared  
47 (FT-IR) spectroscopy as an alternative to WGS for detecting and characterizing GAS  
48 transmission routes. A total of 66 iGAS strains isolated from nine Swiss hospitals during the  
49 COVID-19 post-pandemic increased GAS prevalence were evaluated and compared to 15  
50 strains collected before and 12 during the COVID-19 pandemic. FT-IR measurements and  
51 WGS were conducted for network analysis. Demographic, clinical, and epidemiological data  
52 were collected. Skin and soft tissue infection was the most common diagnosis, followed by  
53 primary bacteremia and pneumonia. Viral co-infections were found in 25% of cases and were  
54 significantly associated with more severe disease requiring intensive care unit admission.  
55 WGS analysis did not reveal emerging GAS genetic distinct variants after the COVID-19  
56 pandemic, indicating the absence of a pandemic-induced shift. FT-IR spectroscopy exhibited  
57 limitations in differentiating genetically distant GAS strains, yielding poor overlap with  
58 WGS-derived clusters. The *emm1*/ST28 gebootype was predominant in our cohort and was  
59 associated with five of the seven deaths recorded, in accordance with the molecular  
60 epidemiological data before the pandemic. Additionally, no notable shift in antibiotic  
61 susceptibility patterns was observed. Our data suggest that mainly non-pathogen related  
62 factors contributed to the recent increased prevalence of iGAS.

63 **Introduction**

64 Group A *Streptococcus* (GAS, aka *Streptococcus pyogenes*) is a pathobiont that causes a wide  
65 spectrum of infections, ranging from pharyngitis and superficial skin infections to severe  
66 invasive infections, such as necrotizing fasciitis, pneumonia or meningitis associated with  
67 high mortality and morbidity rates, with 500,000 estimated deaths annually worldwide [1-3].

68 After a historically low incidence of GAS infections during the COVID-19 pandemic, an  
69 alarmingly increasing incidence of invasive GAS (iGAS) infections has been reported, since  
70 October 2022, in many European countries and in the USA, mostly among children under 10  
71 years of age, including many fatalities [4-7]. Also in Switzerland, since November 2022, a  
72 fourfold increase of the registered iGAS infections in children, including four deaths, has been  
73 reported compared to the pre- COVID-19 pandemic era [8]. So far, there is no evidence for  
74 the emergence of a more virulent clone [9, 10]. In the United Kingdom the pre-pandemic  
75 predominant M1uk clone was detected in the majority of the GAS strains isolated during the  
76 December 2022 outbreak [9]. The causes of the resurgence of iGAS remain somewhat  
77 elusive.

78 The detection and management of outbreaks, particularly in the case of GAS, rely on  
79 understanding transmission routes and genetic diversity. Molecular typing by whole genome  
80 sequencing (WGS) or conventional (Sanger) sequencing of the hypervariable N-terminal  
81 region of the *emm* gene, encoding the surface M protein [11], is crucial for epidemiological  
82 studies and outbreak investigations, although it is time-consuming, expensive and requires  
83 expertise [12, 13]. Alternatively, Fourier-transform infrared (FT-IR) spectroscopy may  
84 provide a cost-effective approach for outbreak analysis by generating a biochemical  
85 fingerprint of the bacterial composition using the full infrared spectrum (4000-400 cm<sup>-1</sup>),  
86 albeit with variable cluster defining cut-offs among different bacterial species and  
87 dependencies on growth conditions [13-19].

88 The aim of this study was to evaluate whether any GAS genomic variations had emerged. To  
89 this end, we compared iGAS strains isolated before, during, and after the COVID-19  
90 pandemic (from January 2013 until May 2023) from patients hospitalized in nine hospitals in  
91 the Regions of Zurich, Graubünden and Geneva using the current gold standard WGS.  
92 Furthermore, we aimed to assess whether FT-IR spectroscopy is a reliable alternative for a  
93 time-efficient detection of GAS outbreaks compared to WGS.

94 **Materials and Methods**

95 *Study period, population, clinical and epidemiological information*

96 The study encompassed 93 strains sourced from the same number of patients with GAS  
97 infection. Among these, 15 strains were retrospectively identified between January 2013 and  
98 December 2019, 18 strains were retrieved from the COVID-19 pandemic period between  
99 February 2020 and September 2022. The remaining 60 strains were prospectively identified  
100 during the latest iGAS resurgence (October 2022 to May 2023) from patients hospitalized in  
101 nine Swiss hospitals: University Hospital Zurich, University Hospital of Geneva, City  
102 Hospital of Zurich, Cantonal Hospital of Graubünden, Cantonal Hospital of Winterthur,  
103 Regional Hospitals of Wetzikon, Uster, Limmatal, and Männedorf. These hospitals  
104 collectively serve an area inhabited by approximately 2 million individuals. Only three of the  
105 participating hospitals admitted pediatric patients. Two patients did not have an invasive  
106 infection (GAS\_036 and GAS\_037), but were included in the study because they were related  
107 to a patient who died from iGAS infection (GAS\_035). Basic demographical, clinical, and  
108 epidemiological data were collected for 74 patients from electronic health records, including  
109 sex, age, diagnosis, co-infections, sampling date and site, as well as the geographical location  
110 of the sampling. Outcomes included admission to the intensive care unit (ICU), intubation and  
111 death related to iGAS. No clinical data were available from the Regional Hospitals of  
112 Limmatal and Männedorf.

113 In order to determine the prevalence of GAS over the years, the number of all GAS strains  
114 detected by culture or molecular techniques in patients admitted to the University Hospital of  
115 Zurich between January 2012 and December 2023 was collected. The GAS strains originating  
116 from blood, joint punctures, cerebrospinal fluid, bronchoalveolar lavage, pleura fluid and soft  
117 tissue were defined as invasive. The definition of the Centre for Disease Control regarding  
118 invasive infection was adopted [20].

119

120 *Ethics approval*

121 This study was approved by the Ethic Committee of Northwest- and Central Switzerland with  
122 the agreement of all Swiss Ethical Committees (BASEC-ID: 2019-01291 as part of the Swiss  
123 Pathogen Surveillance Platform, www.spsp.ch). Patients declining to sign a general consent or  
124 any other declining statement against using data for research purposes were excluded.

125

126 *Bacterial strains*

127 93 GAS strains were collected from the same number of patients hospitalized in the nine  
128 hospitals mentioned above and stored at -80°C. Species identification of all samples was  
129 carried out using Matrix Assisted Laser-Desorption Ionization – Time of Flight (MALDI-  
130 TOF) (MBT Compass 4.1, Bruker Daltonics, Bremen, Germany) using the database BDAL  
131 DB.13.

132

133 *Sample preparation for FT-IR spectroscopy and WGS*

134 Three to five macroscopically identical colonies were subcultured on 5 % sheep blood agar  
135 plates (Biomérieux) for 24±2 hours at 37°C in a static incubator in the presence of 5% CO<sub>2</sub>.  
136 For FT-IR spectroscopy, a 1µl-loop was overloaded with bacteria cells that were then  
137 resuspended in 50 µl ethanol solution (70% v/v) in a 1.5 ml tube containing metal rods. The  
138 suspension was then vortexed extensively and 50 µl of deionized water were added, followed  
139 by another round of vortexing. Fifteen microliters of the homogenized bacterial suspension  
140 were placed on a 96-spot silicon plate (Bruker Daltonics, Bremen, Germany) in four technical  
141 replicates per bacterial isolate. The plates were dried at 37°C for approximately 20 minutes  
142 followed by infrared measurements. For WGS, a lawn was streaked from frozen stocks and  
143 samples were processed as previously described [21, 22].

144

145 *Infrared measurements*

146 An IR-Biotyper (Bruker Daltonics) was used for all measurements according to the  
147 manufacturer's instructions and as previously described [19]. In brief, 12 µl of test standard 1  
148 and 2 (ITRS 1/ ITRS 2) were placed on the 96-spot silica plate and used as controls. The  
149 samples were measured using the OPUS software v8.2.28 (Bruker Daltonics), detecting  
150 carbohydrates spectra within the wavenumber range of 1200 and 900 cm<sup>-1</sup>. Data analysis was  
151 performed using the same software. Isolates with three or more valid replicates in the same  
152 run were included in the analysis.

153

#### 154 *Whole genome sequencing of isolates and comparative genomics*

155 Whole genome sequencing of the clinical isolates was performed at the Institute for Medical  
156 Microbiology, University of Zurich, Switzerland as previously described [21]. *Emm*-typing  
157 was extrapolated from the WGS data using the *emm*-typing tool [23] and MLST typing was  
158 inferred from the WGS data using MLST v.2.7.6 [24], which makes use of the PubMLST  
159 website (<https://pubmlst.org/>) developed by Keith Jolley [25] and sited at the University of  
160 Oxford. The development of that website was funded by the Wellcome Trust.

161 De novo assemblies were built with SPAdes v.3.14.1 using the `-careful` option [26].  
162 Annotation of the resulting assemblies was performed with Prokka v1.14.6 [27]. The created  
163 GFF files were used as input to Roary v3.13.0 to construct the pangenome, for which we used  
164 the command `-e -mafft` that generates a multi-fasta alignment of the core genes [28]. The  
165 average nucleotide identity (ANI) was inferred with pyani v0.2.12 choosing the method  
166 ANIm, which makes use of MUMmer / NUCmer to align the input sequences [29].  
167 Phylogenetic trees were inferred from the aligned core genome using IQTREE [30] under the  
168 GTR+G+I model. Trees and metadata were processed and plotted using the R-packages ape  
169 [31] and ggtree [32].

170 The overlap between clusters derived from FT-IR and whole bacterial genome data  
171 (specifically Average Nucleotide Identity, ANI) was quantified as outlined in Scheier *et al*



172 [19] . In brief FT-IR clusters were inferred by cutting the hierarchical (UPGMA) clustering  
173 tree derived from the Euclidean distance of the FT-IR spectra at a given height, which was  
174 varied over a broad range. ANI-based clusters were defined as the components of the network  
175 obtained by connecting those pairs of nodes whose ANI was above a given threshold. We  
176 used the v-measure to quantify the overlap between these two networks.

177 The genomic data with matched phenotypic information can be downloaded here ([National  
178 Center for Biotechnology Information \(nih.gov\)](https://www.ncbi.nlm.nih.gov/bioproject/528117)).

179

#### 180 *Antibiotic susceptibility testing*

181 Antibiotic susceptibility testing to penicillin, clindamycin and erythromycin was conducted on  
182 pandemic and post-pandemic GAS strains as part of the routine microbiological assessment.  
183 The Kirby-Bauer method was performed in line with the recommendations of the European  
184 Committee on Antimicrobial Susceptibility Testing (EUCAST) in the ISO accredited Institute  
185 of Molecular Microbiology (IMM) in Zurich. Briefly, a 0.5 McFarland standard inoculum  
186 preparation was used. Mueller-Hinton agar was supplemented with 5% defibrinated horse  
187 blood and 20 mg/L  $\beta$ -NAD (MH-F agar). After evenly inoculating the agar with the bacterial  
188 suspension, antimicrobial disks were applied to the agar surface. To detect inducible  
189 clindamycin resistance, erythromycin and clindamycin disks were placed 12-16 mm apart  
190 (edge to edge). The plates were incubated at  $35 \pm 1^\circ\text{C}$  in with 4-6%  $\text{CO}_2$  for  $18 \pm 2$  hours,  
191 after which zones of inhibition were measured to determine susceptibility based on EUCAST  
192 breakpoint tables (version 14.0).

193

#### 194 *Data Analysis*

195 For the patients' clinical characteristics we performed a descriptive statistical analysis.  
196 Continuous variables were presented as mean with range, except for age which was presented  
197 as median with range. Categorical variables were presented as frequency tables. For the

198 association of the patient-related factors with the severity of the disease we chose as  
199 dependent variables the ICU admission and the all-cause in-hospital mortality and performed  
200 a univariable analysis. Due to the rare event problem for the case of obesity (4/74 incidences),  
201 we collapsed this variable with two other related medical conditions, diabetes mellitus and  
202 cardiovascular disease (CVD), based on their clinical relevance and exhibited overlap.  
203 Variables that demonstrated significant (or marginally significant) associations ( $p < 0.07$ ) in  
204 the univariable analysis were taken to multivariable binary logistic regression analysis. The  
205 significance level was set at  $p < 0.05$ . The model fit was evaluated using the Hosmer-  
206 Lemeshow test. All analyses were performed with IBM SPSS Statistics V26 (IBM Corp.,  
207 Armonk, NY, USA).

208

#### 209 *Funding information*

210 This study was supported by the University Of Zurich CRPP Personalized Medicine Of  
211 Persisting Bacterial Infections Aiming to Optimize Treatment and Outcome to S.D.B, and  
212 A.S.Z.; and by grant (INOV00121) from University Hospital Zurich to T.C.S.

213 **Results**

214 *Report of laboratory-confirmed GAS cases at the University Hospital Zurich between January*  
215 *2012 and December 2023*

216 The total number of iGAS strains detected with cultures or molecular techniques from January  
217 2012 to December 2023 reported at the University Hospital Zurich is shown in **Figure 1**. GAS  
218 infections typically have a seasonal pattern, showing a peak during late spring in the northern  
219 hemisphere [33]. During the COVID-19 pandemic (from March 2020 until the suspension of  
220 the pandemic prevention methods in Switzerland, in March 2022), the detection of GAS cases  
221 declined compared to the previous years (**Suppl. Figure 1**) and the number of iGAS was also  
222 historically low (**Figure 1**). In the first quarter of 2023, there was a notable surge in invasive  
223 and non-invasive GAS cases, marking a threefold increase compared to the same month  
224 average in pre-pandemic years (**Figure 1, Suppl. Figure 1**). The number of isolated GAS  
225 strains remained unusually high throughout the first post-pandemic year.

226

227 *Demographic and clinical characteristics of the patients with iGAS infections*

228 93 patients, from whom the 93 GAS strains were isolated, were included in this study. The  
229 clinical data of 74 patients hospitalized in seven Swiss hospitals were included. The clinical  
230 data of the remaining 19 patients (14 from the retrospectively collected strains and five from  
231 the prospectively collected ones) could not be retrieved. 44 patients (59.5%) were male with a  
232 median age of 47.5 years (range 1 to 94 years), nine (6.5%) were under 18 years of age.  
233 Cardiovascular disease (35.1%), diabetes mellitus (17.6%), and solid tumors (9.5%) were the  
234 most common comorbidities. The most common diagnosis of infection was skin and soft  
235 tissue infection (SSTI) with bacteremia (18.9%), whereas necrotizing fasciitis was diagnosed  
236 in five (6.8%) patients. The primary sampling site, representing the majority of cases (64.9%),  
237 was blood, followed by tissue biopsies (13.5%). Notably, 24.3% of cases featured viral co-  
238 infections; six patients (8.2%) were diagnosed with influenza and three (4.1%) with SARS-

239 CoV-2, three (4.1%) with a co-infection with SARS-CoV-2 and influenza and three (4.1%)  
240 with respiratory syncytial virus (RSV). Two patients were diagnosed with varicella zoster  
241 virus (VZV) reactivation. Fifteen patients (20.3%) suffered from toxic shock syndrome (TSS).  
242 A large number required ICU admission (43.2%) and intubation (29.7%). Surgical  
243 debridement was performed in 39 patients (52.7%). Combination antimicrobial therapy was  
244 employed in 38 (51.4%) of cases; in 27 of them (71%) clindamycin was co-administered with  
245 another antibiotic. Immunoglobulin was administered to all fifteen patients with TSS (20.3%).  
246 The average hospitalization duration was 15.6 days, (range 0 - 100 days). We observed an all-  
247 cause mortality rate of 9.5%, with 6 out of 7 deaths specifically attributed to iGAS. The  
248 demographic and clinical characteristics of the patients are summarized in **Table 1**.  
249 The univariable logistic regression analysis revealed significant correlations between ICU  
250 admission and viral coinfections (OR 3.600, 95% CI 1.172-11.057). A marginally significant  
251 correlation between ICU admission, female sex (OR 0.396, 95% CI 0.152-1.027), and the  
252 collapsed variable of obesity, cardiovascular disease and diabetes mellitus (OR 2.500, 95% CI  
253 0.954-6.552) was detected (**Table 2**). All four patients with obesity were admitted to the ICU  
254 (p-Fisher 0.03). No significant correlations were found between the investigated patient-  
255 related variables and the all-cause in-hospital mortality (**Suppl. Table 1**). A multivariable  
256 bimodal logistic regression model for ICU admission confirmed statistically significant  
257 coefficients for female sex (OR 0.256, 95% CI 0.081 - 0.804), viral coinfection (OR 4.094,  
258 95%CI 1.199-13.986) and the collapsed variable (obesity, cardiovascular disease or diabetes  
259 mellitus) (OR 4.595, 95% CI 1.424-14.835) (**Table 2**). The Nagelkerke R square was 0.256  
260 indicating an adequate level of explanatory power and the significance level of the Hosmer-  
261 Lemeshow test was 0.393 indicating a good model fitting.

262

263 *Clinical isolates characteristics*

264 Clinical isolates were genetically characterized to determine their ST and *emm*-type (**Table**  
265 **3**). The *emm* typing yielded successful results in 92 out of 93 strains, detecting 18 different  
266 *emm* types. Among these, *emm1*-type (*emm1.0*, *emm 1.2*, *emm1.3*, *emm1.6*, *emm1.7*) emerged  
267 as the predominant type in 63 cases (68%), followed by *emm12* (*emm12.0*, *emm12.2*,  
268 *emm12.4*) in 7 cases (7.6%). The *emm1*-type/ST-28 was prevalent, and associated with higher  
269 mortality, since it was detected in 5/7 (71%) patients who died.

270 The Kirby-Bauer method was performed on 79 strains in order to determine phenotypical  
271 antimicrobial resistance (**Table 3**). All tested strains were susceptible to penicillin. Only one  
272 strain was found resistant to clindamycin and erythromycin. No inducible clindamycin  
273 resistance was detected.

274

#### 275 *Molecular typing of iGAS*

276 A comprehensive genomic analysis utilizing WGS was performed on a cohort comprising 91  
277 iGAS und 2 non-invasive GAS strains, whose sampling periods spanned through before,  
278 during, and after the COVID-19 pandemic (**Figure 2A and 2B**). Notably, we found a  
279 consistent preservation of sequence-types (STs) across all sampling times, indicating genetic  
280 stability within the GAS population. Intriguingly, most strains associated with the current  
281 GAS upsurge were found to originate from existing genetic lineages circulating before the  
282 pandemic, suggesting a continuum in transmission dynamics rather than a pandemic-induced  
283 shift. The phylogenies did not exhibit large clusters of recent and post-pandemic strains  
284 clearly distinct from the older reference variants refM1uk, ref5005, and ref5448. Ten strains  
285 (GAS\_086, GAS\_032, GAS\_031, GAS\_082, GAS\_070, GAS\_027, GAS\_052, GAS\_046,  
286 GAS\_076, GAS\_048) exhibited a genetic resemblance by core genome phylogeny, possessing  
287 different ST types compared to the predominant ST-28 type. These strains were not confined  
288 to a specific geographic location but were dispersed throughout the country. A high level of  
289 genetic relatedness was found between GAS\_035 and GAS\_037 strains, originating from a

290 patient that died from an iGAS infection and an individual related to the patient, respectively.  
291 FT-IR spectroscopy showed a poor concordance compared to the core genome analysis  
292 performed with the WGS, failing to reliably differentiate genetically distant GAS strains (**Fig.**  
293 **Suppl. 2**).

294 **Discussion**

295 In summary, this multicenter study shows that WGS core genome analysis of GAS strains  
296 isolated in Switzerland before, during, and after the COVID-19 pandemic did not reveal  
297 genetically distinct, emerging variants. The *emm1* ST28 was predominant in our cohort. FT-IR  
298 spectroscopy showed poor overlap with WGS and did not effectively differentiate genetically  
299 distant GAS strains, confirming WGS as the current gold standard for the characterization of  
300 GAS clinical isolates. Moreover, viral coinfections, mainly influenza and SARS-CoV-2, were  
301 significantly associated with a severe iGAS infection requiring an ICU admission.

302 While we found a large *emm1*/ST28 cluster, including the reference strains (refM1uk, ref5005  
303 and ref5448), the absence of outbreak characteristics, such as clustered cases in a specific  
304 geographical region and a high genetic relatedness within potential transmission chains,  
305 suggests that the strains of the current resurgence were part of the diversity already circulating  
306 before the COVID-19 pandemic. The *emm1*/ST28 genotype has been commonly reported  
307 causing iGAS infections [34], consistently indicating its dominance over the years [9, 10, 35,  
308 36]. Accordingly, we observed that in our cohort *emm1*/ST28 was the predominant variant,  
309 present in most patients (5/7) who died from an iGAS infection. Interestingly, we did not find  
310 any clusters originating from the three reference strains refM1uk, ref5005 and ref5448, known  
311 to cause invasive infections [9, 37, 38]. Furthermore, the phenotypic susceptibility testing  
312 revealed a high susceptibility to penicillin, erythromycin and clindamycin, confirming the  
313 known susceptibility patterns over the years without a shift towards more resistant strains, as  
314 reported worldwide [4, 6, 9].

315 The COVID-19 pandemic highlighted the need for rapid epidemic diagnosis in controlling  
316 outbreaks. To our knowledge, this study is the first to compare the time- and cost-effective  
317 FT-IR spectroscopy with WGS for GAS typing and outbreak investigation. FT-IR  
318 spectroscopy showed poor overlap with WGS and did not effectively differentiate genetically  
319 distant GAS strains. GAS, known for its adaptive nature and highly recombining genome,

320 undergoes phenotypic changes during invasive infections, potentially impacting FT-IR  
321 spectroscopy's efficacy, a technique reliant on biochemical fingerprints [39, 40]. Our findings  
322 underscore FT-IR spectroscopy's limitations in characterizing GAS strains during outbreaks,  
323 supporting WGS as the gold standard typing method for GAS. Furthermore, WGS is a  
324 valuable tool for GAS characterization, since it can provide important information on *emm*  
325 type, virulence factors and antibiotic resistance genes.

326 Our epidemiological records from multiple centers across Switzerland confirm the dramatic  
327 increase in iGAS infections, also documented across numerous countries globally [4]. Even  
328 though these infections result in about 500,000 deaths annually worldwide, imposing a  
329 substantial economic burden [11, 41], data on the incidence of iGAS clinical manifestations  
330 remain scarce. At the University Hospital of Zurich, a threefold increase of the number of  
331 invasive and non-invasive GAS strains was reported since December 2022 compared to the  
332 pre-pandemic years, which aligns with the reports of other countries [6, 9]. Within our study,  
333 the most prevalent diagnosis was SSTI, in line with findings from a study conducted in New  
334 Zealand [42], followed by primary bacteremia and pneumonia. In accordance with other  
335 studies [43], viral coinfections, mostly influenza and SARS-CoV-2, were relatively frequent  
336 in our study cohort and significantly associated with a severe disease leading to ICU  
337 admission, supporting the current hypothesis linking the recent iGAS infections outbreak to a  
338 high prevalence of circulating respiratory viruses [10, 35]. Furthermore, we found that female  
339 sex and the metabolic risk factors (cardiovascular disease, obesity and diabetes mellitus) were  
340 also significantly associated with a severe disease requiring an ICU support. The all-cause  
341 mortality in our cohort was 9.5%, comparable with the data published in England [35],  
342 highlighting the severity of iGAS infections.

343 The cause of the global post-pandemic increased GAS infections prevalence remains elusive.  
344 Our findings point out that the recent upsurge does not arise from pathogen-related factors,  
345 prompting further exploration of alternative causes, as proposed in prior studies [6, 9, 10, 44].



346 The current hypothesis suggests that the lack of exposure to GAS and common seasonal  
347 respiratory viruses during the COVID-19 pandemic, due to isolation measures, resulted in  
348 decreased immunity to GAS and seasonal respiratory viruses [35, 37, 43, 45]. After lifting the  
349 COVID-19 pandemic protection measures, an increase and a shift of the seasonal pattern in  
350 seasonal respiratory viral and iGAS infections was observed after two years of their  
351 historically low incidence.

352 This study has some limitations that affect its broader applicability. The sample origin, limited  
353 to specific Swiss regions, may not represent a broader GAS strain diversity. The  
354 retrospectively collected subset of data and the unavailability of clinical information for some  
355 patients does not allow determining risk factors associated with the current increased iGAS  
356 prevalence. Only three of the participating hospitals admitted pediatric patients, leading to an  
357 underrepresentation of minors. To draw more decisive conclusions regarding the risk factors  
358 of iGAS infections, future studies should include larger, diverse samples cohorts from various  
359 regions, encompassing both invasive and non-invasive strains and performing genotypic as  
360 well as phenotypic virulence studies.

361 To the best of our knowledge, this is the biggest data set of invasive GAS strains across  
362 multiple centers in Switzerland, giving a broad view of the post-pandemic increased  
363 prevalence of iGAS infections. The long time-span of the examined GAS strains allowed us to  
364 explore potential genetic changes before and after the COVID-19 pandemic. The absence of  
365 genetic diversity and shift to more resistant strains throughout the years suggests that non-  
366 pathogen related factors may lead to resurgence of iGAS, supporting the theory that the lack  
367 of immunity to GAS and the common respiratory viruses due to the social distancing during  
368 the COVID-19 pandemic could be associated with severe iGAS infections with many  
369 fatalities.

370 **Conclusion**

371 In summary, our study aimed to investigate the genetic characteristics of GAS strains  
372 responsible for the current resurgence of iGAS infection following the COVID-19 pandemic.  
373 WGS-based molecular typing did not uncover genetic changes regarding *emm*-type and  
374 sequence-type (ST) pre- during- and post-pandemic. Moreover, antibiotic susceptibility testing  
375 revealed unchanged susceptibility patterns. The FT-IR spectroscopy limitations in GAS  
376 typing underscore the ongoing importance of WGS in molecular analysis. Our results suggest  
377 that non-pathogen related factors, such as the lack of immunity to GAS and other common  
378 respiratory viruses due to social distancing and wearing masks during the COVID-19  
379 pandemic, may be responsible for the post-pandemic increased prevalence of the iGAS  
380 infections. Further research is needed to improve surveillance methods of iGAS strains.

381 **References**

- 382 1. Nelson, G.E., et al., *Epidemiology of Invasive Group A Streptococcal Infections in the United*  
383 *States, 2005-2012*. Clin Infect Dis, 2016. **63**(4): p. 478-86.DOI: 10.1093/cid/ciw248.
- 384 2. Walker, M.J., et al., *Disease manifestations and pathogenic mechanisms of Group A*  
385 *Streptococcus*. Clin Microbiol Rev, 2014. **27**(2): p. 264-301.DOI: 10.1128/cmr.00101-13.
- 386 3. Andreoni, F., et al., *Clindamycin Affects Group A Streptococcus Virulence Factors and*  
387 *Improves Clinical Outcome*. J Infect Dis, 2017. **215**(2): p. 269-277.DOI: 10.1093/infdis/jiw229.
- 388 4. *World Health Organization (15 December 2022). Disease Outbreak News; Increased incidence*  
389 *of scarlet fever and invasive Group A Streptococcus infection - multi-country*. Available from:  
390 <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON429>.
- 391 5. Barnes, M., et al., *Notes from the Field: Increase in Pediatric Invasive Group A Streptococcus*  
392 *Infections - Colorado and Minnesota, October-December 2022*. MMWR Morb Mortal Wkly  
393 Rep, 2023. **72**(10): p. 265-267.DOI: 10.15585/mmwr.mm7210a4.
- 394 6. Aboulhosn, A., et al., *Increases in group A streptococcal infections in the pediatric population*  
395 *in Houston, TX, 2022*. Clin Infect Dis, 2023.DOI: 10.1093/cid/ciad197.
- 396 7. *Increase in Invasive Group A Strep Infections, 2022–2023*. 2023 February 2, 2023; Available  
397 from: <https://www.cdc.gov/groupastrep/igas-infections-investigation.html>.
- 398 8. *Invasive Infektionen mit Gruppe A Streptokokken (iGAS) bei Kindern; Update vom 31. März*  
399 *2023 - - Statement der PIGS*. Available from:  
400 [https://www.paediatricschweiz.ch/news/zunahme-invasiver-gruppe-a-streptokokken-](https://www.paediatricschweiz.ch/news/zunahme-invasiver-gruppe-a-streptokokken-infektionen-igas/)  
401 [infektionen-igas/](https://www.paediatricschweiz.ch/news/zunahme-invasiver-gruppe-a-streptokokken-infektionen-igas/).
- 402 9. Alcolea-Medina, A., et al., *The ongoing Streptococcus pyogenes (Group A Streptococcus)*  
403 *outbreak in London, United Kingdom in December 2022: a molecular epidemiology study*.  
404 Clinical Microbiology and Infection, 2023.DOI: <https://doi.org/10.1016/j.cmi.2023.03.001>.
- 405 10. de Gier, B., et al., *Increase in invasive group A streptococcal (Streptococcus pyogenes)*  
406 *infections (iGAS) in young children in the Netherlands, 2022*. Euro Surveill, 2023. **28**(1).DOI:  
407 10.2807/1560-7917.Es.2023.28.1.2200941.
- 408 11. Brouwer, S., et al., *Pathogenesis, epidemiology and control of Group A Streptococcus*  
409 *infection*. Nat Rev Microbiol, 2023. **21**(7): p. 431-447.DOI: 10.1038/s41579-023-00865-7.
- 410 12. Bessen, D.E., P.R. Smeesters, and B.W. Beall, *Molecular Epidemiology, Ecology, and Evolution*  
411 *of Group A Streptococci*. Microbiol Spectr, 2018. **6**(5).DOI: 10.1128/microbiolspec.CPP3-0009-  
412 2018.
- 413 13. Teng, A.S.J., et al., *Comparison of fast Fourier transform infrared spectroscopy biotyping with*  
414 *whole genome sequencing-based genotyping in common nosocomial pathogens*. Anal Bioanal  
415 Chem, 2022. **414**(24): p. 7179-7189.DOI: 10.1007/s00216-022-04270-6.
- 416 14. Novais, Â., et al., *Fourier transform infrared spectroscopy: unlocking fundamentals and*  
417 *prospects for bacterial strain typing*. Eur J Clin Microbiol Infect Dis, 2019. **38**(3): p. 427-  
418 448.DOI: 10.1007/s10096-018-3431-3.
- 419 15. Zarnowiec, P., et al., *Fourier Transform Infrared Spectroscopy (FTIR) as a Tool for the*  
420 *Identification and Differentiation of Pathogenic Bacteria*. Curr Med Chem, 2015. **22**(14): p.  
421 1710-8.DOI: 10.2174/0929867322666150311152800.
- 422 16. Hu, Y., et al., *Evaluation of the IR Biotyper for Klebsiella pneumoniae typing and its potentials*  
423 *in hospital hygiene management*. Microb Biotechnol, 2021. **14**(4): p. 1343-1352.DOI:  
424 10.1111/1751-7915.13709.
- 425 17. Azrad, M., et al., *Comparison of FT-IR with whole-genome sequencing for identification of*  
426 *maternal-to neonate transmission of antibiotic-resistant bacteria*. J Microbiol Methods,  
427 2022. **202**: p. 106603.DOI: 10.1016/j.mimet.2022.106603.
- 428 18. Martak, D., et al., *Fourier-Transform InfraRed Spectroscopy Can Quickly Type Gram-Negative*  
429 *Bacilli Responsible for Hospital Outbreaks*. Front Microbiol, 2019. **10**: p. 1440.DOI:  
430 10.3389/fmicb.2019.01440.

- 431 19. Scheier, T.C., et al., *Fourier-transform infrared spectroscopy for typing of vancomycin-*  
432 *resistant Enterococcus faecium: performance analysis and outbreak investigation.* Microbiol  
433 Spectr, 2023. **11**(5): p. e0098423.DOI: 10.1128/spectrum.00984-23.
- 434 20. *Case definitions for infectious conditions under public health surveillance.* Centers for Disease  
435 *Control and Prevention.* MMWR Recomm Rep, 1997. **46**(Rr-10): p. 1-55.
- 436 21. Rätz, A.K., et al., *Limited Adaptation of Staphylococcus aureus during Transition from*  
437 *Colonization to Invasive Infection.* Microbiol Spectr, 2023. **11**(4): p. e0259021.DOI:  
438 10.1128/spectrum.02590-21.
- 439 22. Kolesnik-Goldmann, N., et al., *Comparison of Disk Diffusion, E-Test, and Broth Microdilution*  
440 *Methods for Testing In Vitro Activity of Cefiderocol in Acinetobacter baumannii.* Antibiotics  
441 (Basel), 2023. **12**(7).DOI: 10.3390/antibiotics12071212.
- 442 23. Kapatai, G., et al., *Whole genome sequencing of group A Streptococcus: development and*  
443 *evaluation of an automated pipeline for emm gene typing.* PeerJ, 2017. **5**: p. e3226.DOI:  
444 10.7717/peerj.3226.
- 445 24. Seemann, T., *mlst Github.*
- 446 25. Jolley, K.A. and M.C. Maiden, *BIGSdb: Scalable analysis of bacterial genome variation at the*  
447 *population level.* BMC Bioinformatics, 2010. **11**: p. 595.DOI: 10.1186/1471-2105-11-595.
- 448 26. Bankevich, A., et al., *SPAdes: a new genome assembly algorithm and its applications to*  
449 *single-cell sequencing.* J Comput Biol, 2012. **19**(5): p. 455-77.DOI: 10.1089/cmb.2012.0021.
- 450 27. Seemann, T., *Prokka: rapid prokaryotic genome annotation.* Bioinformatics, 2014. **30**(14): p.  
451 2068-9.DOI: 10.1093/bioinformatics/btu153.
- 452 28. Page, A.J., et al., *Roary: rapid large-scale prokaryote pan genome analysis.* Bioinformatics,  
453 2015. **31**(22): p. 3691-3.DOI: 10.1093/bioinformatics/btv421.
- 454 29. Pritchard, L., et al., *Genomics and taxonomy in diagnostics for food security: soft-rotting*  
455 *enterobacterial plant pathogens.* Analytical Methods, 2016. **8**(1): p. 12-24.DOI:  
456 10.1039/C5AY02550H.
- 457 30. Nguyen, L.T., et al., *IQ-TREE: a fast and effective stochastic algorithm for estimating*  
458 *maximum-likelihood phylogenies.* Mol Biol Evol, 2015. **32**(1): p. 268-74.DOI:  
459 10.1093/molbev/msu300.
- 460 31. Paradis, E. and K. Schliep, *ape 5.0: an environment for modern phylogenetics and*  
461 *evolutionary analyses in R.* Bioinformatics, 2019. **35**(3): p. 526-528.DOI:  
462 10.1093/bioinformatics/bty633.
- 463 32. Yu, G., et al., *ggtree: an r package for visualization and annotation of phylogenetic trees with*  
464 *their covariates and other associated data.* Methods in Ecology and Evolution, 2017. **8**(1): p.  
465 28-36.DOI: <https://doi.org/10.1111/2041-210X.12628>.
- 466 33. Kennis, M., et al., *Seasonal variations and risk factors of Streptococcus pyogenes infection: a*  
467 *multicenter research network study.* Ther Adv Infect Dis, 2022. **9**: p.  
468 20499361221132101.DOI: 10.1177/20499361221132101.
- 469 34. Ekelund, K., et al., *Variations in emm type among group A streptococcal isolates causing*  
470 *invasive or noninvasive infections in a nationwide study.* J Clin Microbiol, 2005. **43**(7): p.  
471 3101-9.DOI: 10.1128/jcm.43.7.3101-3109.2005.
- 472 35. Guy, R., et al., *Increase in invasive group A streptococcal infection notifications, England,*  
473 *2022.* Euro Surveill, 2023. **28**(1).DOI: 10.2807/1560-7917.Es.2023.28.1.2200942.
- 474 36. Gherardi, G., L.A. Vitali, and R. Creti, *Prevalent emm Types among Invasive GAS in Europe and*  
475 *North America since Year 2000.* Front Public Health, 2018. **6**: p. 59.DOI:  
476 10.3389/fpubh.2018.00059.
- 477 37. Peetermans, M., et al., *Clinical and molecular epidemiological features of critically ill patients*  
478 *with invasive group A Streptococcus infections: a Belgian multicenter case-series.* Ann  
479 Intensive Care, 2024. **14**(1): p. 19.DOI: 10.1186/s13613-024-01249-7.
- 480 38. Wilkening, R.V. and M.J. Federle, *Evolutionary Constraints Shaping Streptococcus pyogenes-*  
481 *Host Interactions.* Trends Microbiol, 2017. **25**(7): p. 562-572.DOI: 10.1016/j.tim.2017.01.007.

- 482 39. Feil, E.J., et al., *Recombination within natural populations of pathogenic bacteria: short-term*  
483 *empirical estimates and long-term phylogenetic consequences*. Proc Natl Acad Sci U S A,  
484 2001. **98**(1): p. 182-7.DOI: 10.1073/pnas.98.1.182.
- 485 40. Bao, Y.-J., et al., *Phenotypic differentiation of Streptococcus pyogenes populations is induced*  
486 *by recombination-driven gene-specific sweeps*. Scientific Reports, 2016. **6**(1): p. 36644.DOI:  
487 10.1038/srep36644.
- 488 41. Carapetis, J.R., et al., *The global burden of group A streptococcal diseases*. Lancet Infect Dis,  
489 2005. **5**(11): p. 685-94.DOI: 10.1016/s1473-3099(05)70267-x.
- 490 42. Cannon, J.W., et al., *The economic and health burdens of diseases caused by group A*  
491 *Streptococcus in New Zealand*. Int J Infect Dis, 2021. **103**: p. 176-181.DOI:  
492 10.1016/j.ijid.2020.11.193.
- 493 43. de Gier, B., et al., *Associations between common respiratory viruses and invasive group A*  
494 *streptococcal infection: A time-series analysis*. Influenza Other Respir Viruses, 2019. **13**(5): p.  
495 453-458.DOI: 10.1111/irv.12658.
- 496 44. Ramos Amador, J.T., A. Berzosa Sánchez, and M. Illán Ramos, *Group A Streptococcus invasive*  
497 *infection in children: Epidemiologic changes and implications*. Rev Esp Quimioter, 2023. **36**  
498 **Suppl 1**(Suppl 1): p. 33-36.DOI: 10.37201/req/s01.09.2023.
- 499 45. Nygaard, U., et al., *Invasive group A streptococcal infections in children and adolescents in*  
500 *Denmark during 2022-23 compared with 2016-17 to 2021-22: a nationwide, multicentre,*  
501 *population-based cohort study*. Lancet Child Adolesc Health, 2024. **8**(2): p. 112-121.DOI:  
502 10.1016/s2352-4642(23)00295-x.

503

504 **Figures**

505 **Figure 1 - Number of detected invasive GAS strains at the University Hospital Zurich**  
506 **between January 2012 and December 2023**

507 Invasive GAS (iGAS) strains detected either by culturing or via molecular methods are  
508 included in this graph. The blue color indicates the number of new cases monthly and the red  
509 color the moving average every three months. Q1: months from January to March, Q2:  
510 months from April to June, Q3: months from July to September, Q4: months from October to  
511 December.

512

513 **Figure 2 - Phylogenetic tree of the 93 GAS clinical isolates and three reference strains**  
514 **(refM1uk, ref5005 and ref5448)**

515 Midpoint rooted maximum likelihood phylogenetic trees based on the alignment of the  
516 clinical isolates and reference strains core genes. The scale bar corresponds to the number of  
517 nucleotide substitutions per position. **A.** Phylogenetic tree of all GAS clinical isolates and the  
518 three reference strains (refM1uk, ref5005 and ref5448). **B.** Magnified representation of the  
519 large *emm1*/ST28 cluster (including refM1uk, ref5005 and ref5448) from panel A.

520

521 **Table 1.** Demographic and clinical characteristics of the patients with invasive GAS  
522 infections

523

524 **Table 2.** Results of the univariable and multivariable logistic regression analysis of the  
525 association of patient-related factors with ICU admission (n=32) upon iGAS infection.

526

527 **Table 3.** Molecular and microbiological characteristics of the 93 GAS clinical isolates.

528

529 **Supplementary Figure 1 - Number of detected GAS strains (invasive and non-invasive)**  
530 **at the University Hospital Zurich between January 2012 and December 2023**

531 Invasive and non-invasive GAS strains detected either by culturing or via molecular methods  
532 are included in this graph. The blue color indicates the number of new cases monthly and the  
533 red color the moving average every three months. Q1: months from January to March, Q2:  
534 months from April to June, Q3: months from July to September, Q4: months from October to  
535 December.

536


537 **Supplementary Figure 2 - Assessment of average nucleotide identity (ANI) networks**  
538 **with FT-IR spectroscopy**

539 Overlap (quantified as the v-measure) between FT-IR and ANI-derived clusters for different  
540 cutoffs used for FT-IR (X-axis) and ANI (color) clustering.

541


542 **Supplementary Table 1.** Results of the univariable and multivariable logistic regression  
543 analysis of the association of patient-related factors with all-cause in-hospital mortality (n=7)  
544 upon iGAS infection.

Number of iGAS strains detection






A



B



<b>Characteristics (N=74)</b>	
<b>Sex, n (%)</b>	
Male	44 (59.5)
Female	30 (40.5)
<b>Median age (range), years</b>	47.5 (1-94)
<b>Patients &lt; 18 years old, n (%)</b>	9 (6.5)
<b>Hospital, n (%)</b>	
University Hospital of Zurich	20 (27)
University Hospital of Geneva	17 (23)
City Hospital Zurich	16 (21.6)
Wetzikon Hospital	9 (12.2)
Cantonal Hospital Chur	7 (9.5)
Uster Hospital	4 (5.4)
Cantonal Hospital Winterthur	1 (1.4)
<b>Coexisting conditions, n (%)</b>	
Cardiovascular disease	26 (35.1)
Diabetes mellitus	13 (17.6)
Renal disease	8 (10.8)
Solid tumortumour	7 (9.5)
Alcohol abuse	6 (8.1)
Intravenous drug use	5 (6.8)
Immunosuppression	4 (5.4)
Adipositas	4 (5.4)
Chronic obstructive lung disease	3 (4.1)
Autoimmune disease	2 (2.7)
Viral hepatitis	2 (2.7)
HIV	1 (1.4)
HematologicalHaematological malignancy	0 (0)
<b>No underlying disease, n (%)</b>	30 (40.5)
<b>≥ 1 underlying disease, n (%)</b>	44 (59.5)
<b>Homeless</b>	2 (2.7)
<b>Sampling site, n (%)</b>	
Blood	48 (64.9)

Tissue biopsy	10 (13.5)
Swab	5 (6.8)
Joint fluid	3 (4.1)
Pleural fluid	3 (4.1)
Abscess	3 (4.1)
Bone biopsy	1 (1.4)
Ascites	1 (1.4)
<b>Diagnosis, n (%)</b>	
SSTI with bacteraemia	14 (18.9)
Pneumonia	12 (16.2)
Isolated bacteraemia	10 (13.5)
SSTI without bacteraemia	5 (6.8)
Necrotizing fasciitis	5 (6.8)
Septic arthritis	5 (6.8)
Non pregnancy related endometritis	3 (4.1)
Osteomyelitis	3 (4.1)
Tonsillitis with abscess	3 (4.1)
Septic bursitis	3 (4.1)
Otitis media/mastoiditis without bacteraemia	2 (2.7)
Otitis media/mastoiditis with bacteraemia	2 (2.7)
Tonsillitis without abscess	2 (2.7)
Pharyngitis with bacteraemia	1 (1.4)
Meningitis	1 (1.4)
Pregnancy related endometritis	1 (1.4)
Mediastinitis	1 (1.4)
Endocarditis	1 (1.4)
<b>Toxic shock syndrome, n (%)</b>	15 (20.3)
<b>Septic shock, n (%)</b>	32 (43.5)
<b>Viral co-infection, n (%)</b>	18 (24.3)
Influenza (A or B)	6 (8.2)
SARS-CoV-2	3 (4.1)
SARS-CoV-2 and Influenza (A or B)	3 (4.1)
RSV	3 (4.1)

VZV	2 (2.7)
Rhinovirus	1 (1.4)
<b>ICU admission, n (%)</b>	32 (43.2)
<b>Intubation, n (%)</b>	22 (29.7)
<b>Surgery, n (%)</b>	39 (52.7)
<b>Amputation, n (%)</b>	4 (5.4)
<b>Antimicrobial therapy, n (%)</b>	
Co-Amoxicillin-Clavulanate	39 (52.7)
Clindamycin	36 (48.6)
CeftriaxonCeftriaxone	26 (35.1)
Penicillin	21(28.4)
Piperacillin-Tazobactam	15 (20.3)
Vancomycin	9 (12.2)
Meropenem	4 (5.4)
Clarithromycin	3 (4.1)
Cefepime	3 (4.1)
Gentamycin	2 (2.7)
<b>Combination therapy, n (%)</b>	38 (51.4)
<b>Immunoglobulin, n (%)</b>	15 (20.3)
<b>Duration of hospitalization, mean (range), days</b>	15.6 (0-100)
<b>Duration of ICU hospitalization, mean (range), days</b>	3.2 (0-21)
<b>All-cause mortality, n (%)</b>	7 (9.5)
<b>GAS-related death, n (%)</b>	6 (8.1)

HIV: Human Immunodeficiency Virus, SSTI: Skin and soft tissue infections, ICU: Intensive Care Unit, GAS: Group A Streptococci, SARS-CoV-2: Severe acute respiratory syndrome coronavirus type 2, RSV: Respiratory Syncytial Virus, VZV: Varicella zoster virus

	Odds Ratio	95% Confidence Intervall	p value
<b>Univariable analysis</b>			
Female sex	0.396	0.152, 1.027	0.057
Cardiovascular disease	1.944	0.739, 5.116	0.178
COPD	0.645	0.056, 7.445	0.725
Diabetes mellitus	1.680	0.504, 5.600	0.398
Solid tumour	0.194	0.022, 1.696	0.138
Immunosuppression	0.419	0.042, 4.232	0.461
Alcohol abuse	1.345	0.253, 7.150	0.728
Renal disease	0.766	0.169, 3.471	0.729
Viral coinfection	3.600	1.172, 11.057	0.062
Collapsed metabolic Variable	2.500	0.954, 6.552	
<b>Multivariable analysis</b>			
Sex	0.256	0.081, 0.804	0.020
Collapsed Metabolic Variable	4.595	1.424, 14.835	0.011
Viral coinfection	4.094	1.199, 13.986	0.025
Constant	0.651		0.336

COPD: chronic obstructive pulmonary disease, HIV: human immunodeficiency virus, IBD: inflammatory bowel disease, Collapsed Metabolic Variable: cardiovascular disease, diabetes mellitus and obesity

Nr.	Strain ID	Lab ID	Isolation year	ST	emm type	Inhibition zone (mm)		
						PEN	ERM	CLI
1	GAS_001	23021066	2022	28	1.0	27	26	23
2	GAS_002	23021067	2023	39	4.0	22	22	19
3	GAS_003	23021068	2023	28	1.3	29	27	23
4	GAS_004	23021069	2023	28	1.0	26	24	18
5	GAS_005	23021070	2023	28	1.3	30	28	23
6	GAS_006	23021071	2023	28	1.3	34	31	26
7	GAS_007	CI1224	2017	28	NA	NA	NA	NA
8	GAS_008	CI1271	2017	28	1.0	NA	NA	NA
9	GAS_009	CI1296	2017	28	1.0	NA	NA	NA
10	GAS_010	CI1316	2017	28	1.0	NA	NA	NA
11	GAS_011	CI1453	2018	28	1.0	NA	NA	NA
12	GAS_012	CI1800	2019	1138	1.0	32	29	23
13	GAS_013	CI2261	2019	101	1.0	NA	NA	NA
14	GAS_014	CI348	2013	28	1.0	NA	NA	NA
15	GAS_015	CI350	2013	28	1.0	NA	NA	NA
16	GAS_016	CI407	2013	52	28	NA	NA	NA
17	GAS_017	CI4711	2020	63	77.0	30	12	25
18	GAS_018	CI4839	2020	28	1.0	33	31	25
19	GAS_019	CI5359	2020	59	8.0	37	32	27
20	GAS_020	CI543	2013	28	1.0	NA	NA	NA
21	GAS_021	CI6416	2020	267	1.0	24	22	20
22	GAS_022	CI655	2014	NA	28	NA	NA	NA
23	GAS_023	CI729	2015	167	118	NA	NA	NA
24	GAS_024	CI7790	2021	403	11.1	31	6	9
25	GAS_025	CI780	2015	167	118	NA	NA	NA
26	GAS_026	CI781	2015	101	89	NA	NA	NA
27	GAS_027	CI8226	2023	242	12.4	30	28	22
28	GAS_028	CI8227	2023	28	1.3	32	29	23
29	GAS_029	CI8236	2023	28	1.0	25	24	19
30	GAS_030	CI8237	2023	28	1.0	32	28	22
31	GAS_031	CI8239	2023	242	12.4	33	30	24
32	GAS_032	CI8240	2023	242	1.3	30	28	22
33	GAS_033	CI8241	2023	28	1.3	31	28	23
34	GAS_034	CI8242	2023	28	1.0	32	29	23
35	GAS_035	CI8243	2023	28	1.0	33	30	24
36	GAS_036	CI8244	2023	28	1.0	33	29	24
37	GAS_037	CI8245	2023	28	1.0	31	28	23
38	GAS_038	CI8248	2023	28	1.0	31	29	23
39	GAS_039	CI8249	2023	28	1.0	27	26	22
40	GAS_040	CI8252	2022	28	1.0	30	29	23
41	GAS_041	CI8253	2022	28	1.0	31	29	23
42	GAS_042	CI8254	2022	28	1.0	31	29	23
43	GAS_043	CI8255	2023	28	1.0	32	29	23

44	GAS_044	CI8256	2023	28	1.0	33	28	22
45	GAS_045	CI8257	2023	28	1.0	31	29	23
46	GAS_046	CI8258	2023	36	12	31	28	23
47	GAS_047	CI8259	2023	28	1.0	32	28	23
48	GAS_048	CI8260	2023	36	12	32	28	23
49	GAS_049	CI8261	2023	62	1.0	34	30	24
50	GAS_050	CI8262	2023	28	1.0	29	28	22
51	GAS_051	CI8263	2023	28	1.0	32	29	23
52	GAS_052	CI8265	2023	36	12	32	28	23
53	GAS_053	CI8266	2023	46	22	35	14	31
54	GAS_054	CI8267	2022	39	1.0	26	26	21
55	GAS_055	CI8268	2022	28	1.0	24	26	22
56	GAS_056	CI8269	2023	28	1.0	24	22	18
57	GAS_057	CI8270	2023	28	1.0	26	22	19
58	GAS_058	CI8273	2023	148	1.3	29	26	21
59	GAS_059	CI8274	2023	28	1.3	33	28	23
60	GAS_060	CI8277	2023	28	1.0	28	24	19
61	GAS_061	CI8278	2023	28	1.0	22	23	18
62	GAS_062	CI8279	2022	28	1.0	31	30	19
63	GAS_063	CI8280	2023	314	1.0	25	12	17
64	GAS_064	CI8453	2022	28	1.0	32	29	23
65	GAS_065	CI8466	2022	101	1.0	27	25	19
66	GAS_066	CI8467	2022	28	1.0	33	28	22
67	GAS_067	CI9366	2023	28	1.4	29	25	22
68	GAS_068	CI9367	2023	101	89.4	27	28	22
69	GAS_069	CI9368	2023	62	87.9	26	23	21
70	GAS_070	CI9370	2023	242	12.4	24	22	22
71	GAS_071	CI9375	2022	28	1.7	27	24	19
72	GAS_072	CI9376	2022	28	1.4	27	24	21
73	GAS_073	CI9377	2022	28	1.7	34	32	30
74	GAS_074	CI9378	2022	178	44.0	24	24	20
75	GAS_075	CI9379	2022	190	49.3	28	28	22
76	GAS_076	CI9380	2022	36	12.2	19	22	18
77	GAS_077	CI9381	2022	NA	73.0	26	26	23
78	GAS_078	CI9382	2022	NA	80.0	30	30	27
79	GAS_079	CI9384	2022	137	104.0	33	30	25
80	GAS_080	CI9385	2022	190	49.3	27	26	21
81	GAS_081	CI9387	2022	28	1.4	31	31	24
82	GAS_082	CI9389	2022	242	252.0	26	24	22
83	GAS_083	CI9390	2022	150	212.0	26	26	22
84	GAS_084	FF09716211	2021	772	89.0	35	26	25
85	GAS_085	FS42596242	2022	11	53.0	30	26	25
86	GAS_086	FS49301899	2022	242	1.0	28	23	21
87	GAS_087	FS49818997	2022	28	1.0	32	33	24
88	GAS_088	FS55545334	2022	969	1.0 and 86.2	22	28	20
89	GAS_089	FS69217489	2023	28	1.0	27	24	22

<b>90</b>	GAS_090	FS72033123	2023	28	1.0	28	29	22
<b>91</b>	GAS_091	FS72033369	2023	28	1.0	30	24	22
<b>92</b>	GAS_092	FS72034424	2023	52	1.0	27	24	21
<b>93</b>	GAS_093	FS72034435	2023	28	1.0	29	24	20

NA: not available